skip to main content
Close Icon We use cookies to improve your website experience.  To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy.  By continuing to use the website, you consent to our use of cookies.
Global Search Configuration

Refine Results

Clear All

Specialism

Show More

Resources

Show More

Show More

Products

Show More

Show More

99+ Total results for product and free and sample content found

Scrip

J.P. Morgan Conference Updates

By Mandy Jackson 17 Jan 2020

JP_Morgan_Notebook_Day_1

Updates and coverage of the 2020 J.P. Morgan Healthcare Conference in San Francisco.

Skipta

Skipta: Digital Clutter Infographic

17 Jan 2020

Inforgraphic

Explore the challenges in digital marketing that can make it difficult for you to directly connect with your specific target audience. Let Skipta’s exclusive perspectives be your guide.

Pink Sheet

A Visual Guide To US FDA's Evolutionary Decade In Review

By Brenda Sandburg 16 Jan 2020

FDAs_Evolutionary_Decade_In_Review

An interactive timeline shows the news of the past decade and the evolution of US FDA policies. Click on each year for a full list of events and see the accompanying article.

Topic FDA Policy and regulation

Scrip

O’Day Lays Out Plan For Gilead’s Continued HIV Dominance

By Joseph Haas 15 Jan 2020

ODay_Lays_Out_Plan

Biktarvy’s powerful sales growth and the potential of a first-in-class capsid inhibitor in both prevention and heavily treatment-experienced patients are key to Gilead’s plan for staying on top in HIV.

Scrip

Korea 2020 Outlook: Hopes Of Turnaround Amid Potential Deals, Biosimilar Launches, Biologics Law

By Jung Won Shin 15 Jan 2020

Korea_2020_Outlook_Hopes_Of_Turnaround

After a year full of disappointing and unexpected events, the South Korean pharma sector is hoping for a turnaround in 2020, with expected biosimilar launches in global markets, progress in drug pipelines, large IPOs and implementation of a new law on cutting-edge biologics.

Topic Clinical Trials Deal trends

Generics Bulletin

California Plans To Create Own Generics Label

By Aidan Fry 15 Jan 2020

California_Plans_To_Create_Own_Generics_Label

California’s 2020-2021 fiscal budget includes plans to work with manufacturers to establish the state’s own generics label. But industry is sceptical that the initiative will deliver the savings that the US state hopes for.

HBW Insight

OTC Zantac And Private Label Ranitidine Numerous In FDA Recall Updates

15 Jan 2020

OTC_Zantac_And_Private_Label

In addition to Sanofi, firms recalling OTC ranitidine products with documentation included in FDA's database updates through 9 January are Amneal Pharmaceuticals, Preferred Pharmaceuticals, which distributed products made by Amneal, and Granules India Ltd.

HBW Insight

Bayer Harnessing Skin Microbiome In New Product Development

By Tom Gallen 15 Jan 2020

Bayer_Harnessing_Skin_Microbiome

Bayer has teamed up with skin microbiome specialist Azitra to develop consumer health products for a host of conditions. 

Pink Sheet

EU 2019 Approvals: Novel Therapies Make Strong Showing

By Ian Schofield 15 Jan 2020

EU_2019_Approvals_Novel_Therapies

Bluebird bio’s gene therapy Zynteglo, Akcea’s antisense drug Waylivra and BioMarin’s enzyme substitution therapy Palynziq were among the novel innovative medicines that were approved in Europe in 2019. 

Next steps

Getting a demo tailored to your needs is the best way to see how our solutions will help you gain an advantage.

Request live demo now:

Our team is always happy to hear from you. Please call us at:

  • US Toll-Free  : +1 888 670 8900
  • US Toll           : +1 908 547 2200
  • UK & Europe : +44 (20) 337 73737
  • Australia        : +61 2 8705 6907
  • Japan              : +81 3 6273 4260

Or please submit your inquiry via the form so that we can provide you the best possible customer service.

Have an immediate and specific information need?

Browse and buy from 1000s of analysis and research reports now: